To compare the effect ofSTING agonist monotherapy on ascites accumulation and tumour burden in comparisonwith vehicle-treated mice, the STING agonist-treated mice were sacrificed when thevehicle mice reached endpoint (abdominal diameter of ≥35 mm). This evidence concerns the gene STING1 and neoplasm.